Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 01.10.2024       Formycon AG

Company Name: Formycon AG ISIN: DE000A1EWVY8   Reason for the research: FYB202 approval in EU and US Recommendation: Buy from: 01.10.2024 Target price: €82 Target price on sight of: 12 months Last rating change: - Analyst: Simon Scholes First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000 [ … ]
Mon, 30.09.2024       Formycon AG

Press Release // September 30, 2024 Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) OtulfiTMreceived FDA approval for both subcutaneous and intravenous formulations, to treat the same conditions as Stelara®   Approval represents the third successful FDA approval for a Formycon biosimilar, two of them in  [ … ]
Fri, 27.09.2024       Formycon AG

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz) Planegg-Martinsried, Germany, September 27, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the U.S. Food and Drug Administration (“FDA”) today approved FYB202/OtulfiTM [ … ]
Fri, 27.09.2024       Formycon AG

Press Release // September 27, 2024Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases FYB202/Otulfi® received European Commission (EC) approval for both subcutaneous and intravenous formulations, providing a high-quality treatment option for European [ … ]
Tue, 17.09.2024       Formycon AG

Press Release // September 17, 2024  Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna   Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Tue, 17.09.2024       Formycon AG

Press Release // September 17, 2024  Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna   Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Mon, 19.08.2024       Formycon AG

Company Name: Formycon AG ISIN: DE000A1EWVY8   Reason for the research: H1/24 results Recommendation: Buy from: 19.08.2024 Target price: €80 Target price on sight of: 12 months Last rating change: - Analyst: Simon Scholes First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analy [ … ]
Tue, 13.08.2024       Formycon AG

Press Release // August 13, 2024 Formycon reports a strong first half-year with multiple milestones achieved Successful business development characterized by key operational, clinical, and regulatory milestones Group revenue and EBITDA in line with expectations Operating results of FYB201 in the first half of the year significantly exceeded ex [ … ]
Wed, 07.08.2024       Formycon AG

Press Release // August 7, 2024   Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences   Planegg-Martinsried, Germany – Formycon AG (FWB: FYB) today announced details for the financial and earnings conference call for the first half of the 2024 fiscal year on August 13, 2 [ … ]
Tue, 06.08.2024       Formycon AG

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Formycon AG increases its outlook for the 2024 fiscal year Planegg-Martinsried, Germany, August 06, 2024 – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Company”) has today decided, based on the preliminary half-year figures, to raise its guidance for t [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Saturday, 12.10.2024, Calendar Week 41, 286th day of the year, 80 days remaining until EoY.